Bacterial coinfection in influenza pneumonia: Rates, pathogens, and outcomes
Patricia S Bartley1, Abhishek Deshpande1,2, Pei-Chun Yu3
1Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio.
Background:
Evidence from pandemics suggests that influenza is often associated with bacterial coinfection. Among patients hospitalized for influenza pneumonia, we report the rate of coinfection and distribution of pathogens, and we compare outcomes of patients with and without bacterial coinfection.
Methods:
We included adults admitted with community-acquired pneumonia (CAP) and tested for influenza from 2010 to 2015 at 179 US hospitals participating in the Premier database. Pneumonia was identified using an International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) algorithm. We used multiple logistic and gamma-generalized linear mixed models to assess the relationships between coinfection and inpatient mortality, intensive care unit (ICU) admission, length of stay, and cost.
Results:
Among 38,665 patients hospitalized with CAP and tested for influenza, 4,313 (11.2%) were positive. In the first 3 hospital days, patients with influenza were less likely than those without to have a positive culture (10.3% vs 16.2%; P < .001), and cultures were more likely to contain Staphylococcus aureus (34.2% vs 28.2%; P = .007) and less likely to contain Streptococcus pneumoniae (24.9% vs 31.0%; P = .008). Of S. aureus isolates, 42.8% were methicillin resistant among influenza patients versus 53.2% among those without influenza (P = .01). After hospital day 3, pathogens for both groups were similar. Bacterial coinfection was associated with increased odds of in-hospital mortality (aOR, 3.00; 95% CI, 2.17-4.16), late ICU transfer (aOR, 2.83; 95% CI, 1.98-4.04), and higher cost (risk-adjusted mean multiplier, 1.77; 95% CI, 1.59-1.96).
Conclusions:
In a large US inpatient sample hospitalized with influenza and CAP, S. aureus was the most frequent cause of bacterial coinfection. Coinfection was associated with worse outcomes and higher costs.
Insights
Bacterial coinfection in influenza patients significantly increases mortality risk and healthcare costs. Staphylococcus aureus was the most common bacterial cause, highlighting the need for targeted interventions during influenza seasons.
Area of Science:
- Infectious Diseases
- Pulmonology
- Critical Care Medicine
Background:
- Influenza pandemics are frequently complicated by bacterial coinfections.
- Understanding the epidemiology and impact of bacterial coinfection in influenza patients is crucial for improving patient outcomes.
Purpose of the Study:
- To determine the rate and causative pathogens of bacterial coinfection in hospitalized influenza patients.
- To compare the clinical outcomes and costs associated with bacterial coinfection in influenza patients versus those without coinfection.
Main Methods:
- Analysis of a large US inpatient database (Premier) from 2010-2015.
- Inclusion of adult patients hospitalized with community-acquired pneumonia (CAP) and tested for influenza.
- Utilized logistic and gamma-generalized linear mixed models to assess coinfection's impact on mortality, ICU admission, length of stay, and cost.
Main Results:
- 11.2% of hospitalized CAP patients tested positive for influenza.
- Staphylococcus aureus was the most frequent bacterial coinfection in influenza patients (34.2%), particularly early in hospitalization.
- Bacterial coinfection was significantly associated with increased in-hospital mortality (aOR 3.00), late ICU transfer (aOR 2.83), and higher costs (multiplier 1.77).
Conclusions:
- Staphylococcus aureus is the predominant bacterial pathogen causing coinfection in hospitalized influenza patients in the US.
- Bacterial coinfection significantly worsens patient outcomes, leading to higher mortality rates and increased healthcare expenditures.
More Related Videos
10:47Using Bioluminescent Imaging to Investigate Synergism Between Streptococcus pneumoniae and Influenza A Virus in Infant Mice
Published on: April 14, 2011
13:45A Precise Pathogen Delivery and Recovery System for Murine Models of Secondary Bacterial Pneumonia
Published on: September 21, 2019
Related Concept Videos
Pneumonia II: Pathophysiology
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Viral Recombination
